



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Availability:

This version is available at: <https://hdl.handle.net/11585/523323> since: 2015-12-09

Published:

DOI: <http://doi.org/10.1200/JCO.2014.56.8253>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

Association Between *BRAF* V600E Mutation and Recurrence of Papillary Thyroid Cancer

Mingzhao Xing, Ali S. Alzahrani, Kathryn A. Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian, Federica Vianello, R. Michael Tuttle, Eyal Robenshtok, James A. Fagin, Efisio Puxeddu, Laura Fugazzola, Agnieszka Czarniecka, Barbara Jarzab, Christine J. O'Neill, Mark S. Sywak, Alfred K. Lam, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Hirotaka Nakayama, Roderick Clifton-Bligh, Giovanni Tallini, Elizabeth H. Holt, and Vlasta Sýkorová

Purpose

To investigate the prognostic value of *BRAF*V600E mutation for the recurrence of papillary thyroid cancer (PTC).

Patients and Methods

This was a retrospective multicenter study of the relationship between *BRAF* V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months).

Results

The overall *BRAF*V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of *BRAF*V600E mutation–positive and 11.6% (125 of 1,082) of *BRAF*V600E mutation–negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in *BRAF* mutation–positive versus –negative patients ($P < .001$), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and various conventional pathologic factors. Significant association between *BRAF* mutation and PTC recurrence was also found in patients with conventionally low-risk disease stage I or II and micro-PTC and within various subtypes of PTC. For example, in *BRAF* mutation–positive versus –negative follicular-variant PTC, recurrence occurred in 21.3% (19 of 89) and 7.0% (24 of 342) of patients, respectively, with recurrence rates of 53.84 (95% CI, 34.34 to 84.40) versus 19.47 (95% CI, 13.05 to 29.04) per 1,000 person-years ($P < .001$) and an HR of 3.20 (95% CI, 1.46 to 7.02) after adjustment for clinicopathologic factors. *BRAF* mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories.

Conclusion

This large multicenter study demonstrates an independent prognostic value of *BRAF* V600E mutation for PTC recurrence in various clinicopathologic categories.

Papillary thyroid cancer (PTC) is a common endo-crine malignancy, which accounts for 80% to 85% of all thyroid cancers, and can be classified into several subtype variants, including the common conventional PTC (CPTC), follicular-variant PTC (FVPTC), and a few uncommon variants.^{1,2} Although PTC is generally a highly curable disease, disease recurrence is common, and a subgroup of patients die, particularly when disease recurrence occurs.³⁻⁵ These patients need to be identified for

appropriately more-aggressive treatments to reduce the chance of disease recurrence and progression. Clinical decisions regarding these patients are classically based on clinicopathologic risk criteria, which are often inaccurate, sometimes making the current risk stratification of PTC clinically challenging.

In recent years, prognostic molecular markers have been vigorously sought to improve risk stratification of PTC, among which *BRAF* V600E mutation has received the widest attention. *BRAF* V600E is a major oncogenic mutation in PTC, which promotes PTC tumorigenesis by aberrantly activating

the MAP kinase pathway.⁶ Many studies have demonstrated an association of *BRAF* V600E mutation with aggressive clinicopathologic characteristics of PTC,⁶⁻⁹ showing promise of this mutation as a prognostic molecular marker for PTC. The association of *BRAF* V600E mutation with PTC recurrence demonstrated in several previous studies has particularly important clinical relevance. However, these studies represented mostly single-institution studies with relatively small series of patients, and the results were sometimes inconsistent. This makes debatable the prognostic value of *BRAF* V600E mutation in the management of PTC. Also, the important issue of whether the prognostic value of *BRAF* V600E mutation holds in individual sub-type variants of PTC, such as FVPTC, has not been established, because previous studies were mostly performed collectively in all PTC variants, and their sample sizes did not provide sufficient power to stratify by variant. Here, we investigated the role of *BRAF* V600E mutation in the recurrence of PTC in a large multicenter study with the goal of establishing its prognostic value for PTC recurrence.

This study was conducted at 16 medical centers in eight countries, including the Johns Hopkins Medical Institution, University of Pittsburgh Medical Center, Memorial Sloan-Kettering Cancer Center, and Yale University in the United States; medical centers at the University of Pisa, University of Perugia, University of Milan, University of Padua, and University of Bologna in Italy; Kanagawa Cancer Center in Yokohama, Japan; Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology in Poland; medical centers at Griffith University and University of Sydney in Australia; Hospital La Paz Health Research Institute in Spain; the Institute of Endocrinology in Prague, Czech Republic; and the University of Ulsan in South Korea.

The same study patients and institutions from a recent study¹⁰ plus additional patients and institutions participated in this study. Briefly, patients were consecutively selected at each center over differing time periods spanning 1978 to 2011. Patients with PTC of all types were selected at all centers, except for Memorial Sloan-Kettering Cancer Center and Kanagawa Cancer Center, where patients with relatively more advanced disease were treated. All patients had been treated for PTC with total thyroidectomy, and therapeutic neck dissection and dissection extents were performed as clinically indicated. Pathologic diagnoses of PTC and variants were made based on WHO criteria and documented in our peer-reviewed publications.¹¹⁻²⁵ Postoperative treatments included standard thyroid-stimulating hormone suppression at appropriate levels and radioiodine (ie, iodine-131 [¹³¹I]) ablation (Appendix Table A1, online only) in patients at all centers, except for Kanagawa Cancer Center, where no ¹³¹I treatment was used. PTC recurrence was defined as recurrent or persistent disease per authoritative histologic, cytologic, radiographic, or biochemical criteria.^{26,27} Local, regional, and distant recurrences were all included. Follow-up time was defined as the time from initial surgical treatment to discovery of PTC recurrence or, in cases of no recurrence, to the most recent clinic visit.

This was a retrospective study, as described recently,¹⁰ which was approved by the institutional review board of each center, and informed patient consent was obtained where required. Patient consent was waived in some cases after institutional review board review, because the study only involved the use of thyroid tumor tissues and collection of clinicopathologic information. Disease stages of PTC were defined based on the American Joint Committee on Cancer staging system. Genomic DNA isolated from primary PTC tumors was sequenced at exon 15 of the *BRAF* gene to identify *BRAF* V600E

mutation, as described in our previously published studies.¹¹⁻²⁵ In all cases, *BRAF* V600E mutation status was examined after the surgical and radioiodine treatments and had no impact on the selection of treatments for patients. A uniform protocol designed for this study was used at all centers to obtain clinicopathologic information from the medical records. Data from all 16 centers were pooled for the analysis of the relationship between *BRAF* V600E mutation and recurrence of PTC.

Recurrence rates per person-year were calculated by dividing the number of recurrences by the total follow-up time, and Poisson regression was used to calculate the 95% CIs and compare across *BRAF* V600E mutation status. Kaplan-Meier survival curves and log-rank tests, censoring patients at the time of last follow-up or 15 years, and Cox proportional hazards regression analysis, censoring patients at the time of last follow-up, were used to compare recurrence by *BRAF* V600E mutation status. A second proportional hazards regression model adjusted for patient age at diagnosis, sex, and medical center, along with a third model that additionally adjusted for tumor size, extrathyroidal invasion, lymph node metastasis, multifocality, and PTC subtype, was used to examine the independent effect of *BRAF* V600E mutation. The covariates were tested for the proportional hazards assumption using the assess statement in SAS software (version 9.3; SAS Institute, Cary, NC). The covariate medical center violated the proportional hazards assumption, and consequently, stratified models were used. A sensitivity analysis, excluding patients who did not experience recurrence but were observed for < 3 years, was performed to address concerns of shorter follow-up times at some centers. Synergy indexes (SIs), as described by Hosmer and Lemeshow,²⁸ were calculated to examine the additive interactions of *BRAF* V600E mutation with classical clinicopathologic risk factors in affecting the recurrence of PTC. All analyses were performed using SAS software (version 9.3). All reported *P* values were two sided, and significance was set at *P* < .05.

We studied a total of 2,099 patients (1,615 women and 484 men) across the 16 centers, with a median age of 45 years (interquartile range [IQR], 34 to 58 years). Patient age, sex, *BRAF* V600E mutation status, PTC recurrence, and follow-up time are summarized overall, by medical center, and by country in Table 1. The overall *BRAF* V600E mutation prevalence was 48.5%, and the overall PTC recurrence was seen in 16.1% of patients, comparable to the literature.⁶⁻⁸ The overall median follow-up time for all patients was 36 months (IQR, 14 to 75 months). The median follow-up time was 35 months (IQR, 15 to 78 months) in the *BRAF* V600E-positive group and 36 months (IQR, 13 to 72 months) in the *BRAF* V600E-negative group (*P* = .37). ¹³¹I doses used in the initial treatment of patients were not different between *BRAF* mutation-positive and -negative groups at most individual centers, but they were higher in *BRAF* mutation-positive patients at some centers and in the overall analysis of all patients (Appendix Table A1, online only).

The number of patients and proportion with recurrence, recurrence rates per 1,000 person-years, and hazard ratios (HRs) for all patients with PTC and by subtype are listed in Table 2. For all patients, 20.9% (213 of 1,017) of *BRAF* mutation-positive patients and 11.6% (125 of 1,082) of *BRAF* mutation-negative patients experienced recurrence. Recurrence rates were significantly higher for *BRAF* mutation-positive compared with -negative patients (47.71 v 26.03

Table 1. Demographic and Clinical Characteristics, *BRAF* V600E Mutation, Recurrence, and Follow-Up Time by Medical Center and Country

Location	No. of Patients	Age at Diagnosis (years)		Male Sex		<i>BRAF</i> V600E Mutation		Recurrence, n (%)						Follow-Up Time (months)			
		Median	IQR	No.	%	No.	%	All		<i>BRAF</i> V600E Positive		<i>BRAF</i> V600E Negative		All Patients		Patients With No Recurrence	
								No.	%	No.	%	No.	%	Median	IQR	Median	IQR
Medical Center																	
Johns Hopkins Hospital	387	45	35 to 57	101	26	151	39	53	14	33	22	20	9	12	1 to 28	11	1 to 28
University of Pittsburgh	169	52	38 to 63	42	25	101	60	10	6	9	9	1	2	19	11 to 26	18	10 to 25
Memorial Sloan-Kettering Cancer Center	135	50	35 to 63	44	33	64	47	35	26	26	41	9	13	96	1 to 144	78	1 to 132
Yale University	18	36	32 to 49	4	22	8	44	3	17	2	25	1	10	5	1 to 14	3	1 to 14
University of Pisa	189	38	28 to 51	47	25	65	34	44	23	22	34	22	18	72	16 to 180	132	48 to 192
University of Perugia	117	49	37 to 59	32	27	76	65	23	20	12	16	11	27	21	6 to 39	18	5 to 40
University of Milan	110	42	34 to 55	24	22	38	35	23	21	7	18	16	22	48	24 to 64	58	26 to 70
University of Padua	135	48	39 to 57	32	24	87	64	17	13	10	12	7	15	26	22 to 30	26	22 to 31
University of Bologna	35	40	32 to 52	8	23	20	57	7	20	5	25	2	13	29	15 to 40	29	22 to 40
Kanagawa Cancer Center	49	55	41 to 65	16	33	33	67	19	39	15	45	4	25	68	28 to 75	73	61 to 78
Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology	99	49	33 to 59	10	10	42	42	4	4	2	5	2	4	48	42 to 53	48	43 to 54
Griffith University	76	40	34 to 56	20	26	34	45	4	5	3	9	1	2	42	4 to 82	40	2 to 79
University of Sydney	95	44	34 to 59	20	21	55	58	21	22	11	20	10	25	103	63 to 135	114	74 to 150
Hospital La Paz Health Research Institute	66	42	32 to 54	11	17	28	42	13	20	9	32	4	10	41	30 to 57	45	30 to 57
Institute of Endocrinology, Prague	222	47	31 to 60	39	18	71	32	22	10	12	17	10	7	50	29 to 85	50	30 to 84
University of Ulsan	197	43	35 to 52	34	17	144	73	40	20	35	24	5	9	105	58 to 120	109	69 to 121
Country																	
United States	709	47	36 to 58	191	27	324	46	101	14	70	22	31	8	16	2 to 35	15	1 to 30
Italy	586	44	34 to 55	143	24	286	49	114	19	56	20	58	19	32	18 to 63	36	23 to 75
Japan	49	55	41 to 65	16	33	33	67	19	39	15	45	4	25	62	28 to 75	73	61 to 78
Poland	99	49	33 to 59	10	10	42	42	4	4	2	5	2	4	48	42 to 53	48	43 to 54
Australia	171	43	34 to 57	40	23	89	52	25	15	14	16	11	13	74	32 to 118	78	35 to 120
Spain	66	42	32 to 54	11	17	28	42	13	20	9	32	4	10	41	30 to 57	45	30 to 57
Czech Republic	222	47	31 to 60	39	18	71	32	22	10	12	17	10	7	50	29 to 85	50	30 to 84
South Korea	197	43	35 to 52	34	17	144	73	40	20	35	24	5	9	105	58 to 120	109	69 to 121
Overall	2,099	45	34 to 58	484	23	1,017	48	338	16	213	21	125	12	36	14 to 75	37	15 to 79

Abbreviation: IQR, interquartile range.

per 1,000 person-years), with an unadjusted HR of 1.82 (95% CI, 1.46 to 2.28), which remained significant after adjustment for patient age and sex and stratification by medical center (HR, 1.63; 95% CI, 1.29 to 2.06) and after additional adjustment for tumor size, extrathyroidal invasion, lymph node metastasis, multifocality, and PTC subtype (HR, 1.38; 95% CI, 1.07 to 1.80).

Restricting the analysis to patients with CPTC (Table 2), *BRAF* V600E mutation prevalence was 56.1% (813 of 1,448). In CPTC, 20.7% (168 of 813) of *BRAF* mutation-positive patients and 12.4% (79 of 635) of *BRAF* mutation-negative patients experienced recurrence. Recurrence rates were significantly higher for *BRAF* mutation-positive compared with -negative patients (44.92 v 25.63 recurrences per 1,000 person-years), with an unadjusted HR of 1.75 (95% CI, 1.34 to 2.29), which remained significant after adjustment for patient age and sex and stratification by center (HR, 1.48; 95% CI, 1.11 to 1.96) and after additional adjustment for pathologic characteristics (HR, 1.46; 95% CI, 1.08 to 1.99).

Restricting the analysis to patients with FVPTC (Table 2), the *BRAF* V600E mutation prevalence was 20.6% (89 of 431). In FVPTC, 21.3% (19 of 89) of *BRAF* mutation-positive patients and 7.0% (24 of 342) of *BRAF* mutation-negative patients experienced recurrence. Recurrence rates were significantly higher for *BRAF* mutation-positive compared with -negative patients (53.84 v 19.47 per 1,000 person-years), with an HR of 2.76 (95% CI, 1.51 to 5.06), which increased after adjustment for patient age and sex and stratification by center (HR, 4.02; 95% CI, 1.95 to 8.28) and remained significant after additional adjustment for pathologic characteristics (HR, 3.20; 95% CI, 1.46 to 7.02).

A sensitivity analysis excluding patients who did not experience recurrence but were observed for < 3 years was performed. The resulting person-year rates were slightly higher for both *BRAF* V600E mutation-positive and -negative patients, but the risk ratios were similar to those reported for the full sample (data not shown).

Table 2. Relationship Between *BRAF* V600E Mutation and Tumor Recurrence in PTC of Various Subtype Variants

Type of PTC	BRAF Mutation		Tumor Recurrence				Recurrence Rates													
	Overall		BRAF V600E Positive		BRAF V600E Negative		BRAF V600E Positive			BRAF V600E Negative										
	No.	%	No.	%	No.	%	Person-Years of Follow-Up	Per 1,000 Person-Years	95% CI	Per 1,000 Person-Years	95% CI	P‡	HR	95% CI	HR	95% CI	HR	95% CI		
All types	1,017 of 2,099	48.5	338 of 2,099	16.1	213 of 1,017	20.9	125 of 1,082	11.6	9,266.1	47.71	41.72 to 54.57	26.03	21.85 to 31.02	<.001	1.82	1.46 to 2.28	1.63	1.29 to 2.06	1.38	1.07 to 1.80
CPTC	813 of 1,448	56.1	247 of 1,448	17.1	168 of 813	20.7	79 of 635	12.4	6,822.2	44.92	38.62 to 52.26	25.63	20.56 to 31.95	<.001	1.75	1.34 to 2.29	1.48	1.11 to 1.96	1.46	1.08 to 1.99
FVPTC	89 of 431	20.6	43 of 431	10.0	19 of 89	21.3	24 of 342	7.0	1,585.7	53.84	34.34 to 84.40	19.47	13.05 to 29.04	<.001	2.76	1.51 to 5.06	4.02	1.95 to 8.28	3.20	1.46 to 7.02

Abbreviations: CPTC, conventional papillary thyroid cancer; FVPTC, follicular-variant papillary thyroid cancer; HR, hazard ratio; PTC, papillary thyroid cancer.

*Model one was unadjusted.

†Model two was adjusted for patient age and sex and stratified by medical center.

#Model three was additionally adjusted for tumor size, extrathyroidal invasion, lymph node metastasis, and multifocality (and PTC subtypes for all-types group).

\$P values from Poisson regression comparing *BRAF* mutation-positive and -negative groups.




Fig 1. Kaplan-Meier survival curves of effect of *BRAF* V600E mutation status on disease recurrence-free probability in patients with various types of papillary thyroid cancer (PTC). Comparison of recurrence-free survival of patients, represented by indicated log-rank and *P* values in each panel, was performed between *BRAF* V600E-negative and -positive groups for (A) all patients, (B) those with conventional PTC, and (C) those with follicular-variant PTC. Follow-up time truncated at 15 years.

A significant association of *BRAF* V600E mutation with decreased recurrence-free probability is shown in Kaplan-Meier survival curves for all PTC (Fig 1A), CPTC only (Fig 1B), and FVPTC only (Fig 1C). We also compared the effects of *BRAF* V600E mutation and several classical clinicopathologic factors (Fig 2). In comparison with




Fig 2. Kaplan-Meier survival curves of interaction of *BRAF* V600E mutation with clinicopathologic risk factors in affecting disease-free probability in patients with papillary thyroid cancer (all types). (A) Lymph node metastasis (LNM) and *BRAF* V600E mutation, (B) tumor extrathyroidal extension (EXT) and *BRAF* V600E mutation, and (C) patients age \geq 60 years and *BRAF* V600E mutation. In each panel, *P* values were from log-rank tests, adjusted for multiple comparisons, comparing each stratum with patients negative for both *BRAF* V600E mutation and indicated clinicopathologic factor. Follow-up time truncated at 15 years.

patients negative for both *BRAF* V600E mutation and lymph node metastasis, those with either *BRAF* mutation or lymph node metastasis had a lower recurrence-free probability, and the probability was further reduced with coexisting mutation and lymph node metastasis

Table 3. Interactions of *BRAF* V600E With Conventional Risk Factors in Recurrence of PTC (all types): Synergy Test

Risk Factor for Interaction With <i>BRAF</i> V600E	Synergy Index*	95% CI
Patient age \geq 45 years	3.22	0.69 to 15.01
Patient age \geq 60 years	2.15	1.11 to 4.19
Lymph node metastasis	1.10	0.80 to 1.49
Extrathyroidal invasion	1.12	0.76 to 1.66

NOTE. Test method from Hosmer and Lemeshow.²⁸

Abbreviation: PTC, papillary thyroid cancer.

*Synergy index different than 1 represents significant additive interaction; > 1 represents synergism; < 1 represents antagonism. There was significant synergistic interaction between *BRAF* V600E mutation and patient age ≥ 60 years in affecting recurrence of PTC. There were no significant interactions between *BRAF* V600E mutation and patient age ≥ 45 years, lymph node metastasis, or extrathyroidal invasion.

(Fig 2A). Similarly, in comparison with patients negative for both *BRAF* mutation and extrathyroidal invasion, presence of either *BRAF* mutation or extrathyroidal invasion was significantly associated with a more rapid decline in the recurrence-free probability curve, and the curve declined further with coexisting mutation and extrathyroidal invasion (Fig 2B). Regarding patient age, in comparison with age < 60 years and *BRAF* mutation negativity, age < 60 years with *BRAF* mutation or age ≥ 60 years without *BRAF* mutation was significantly associated with a more rapid decline in the recurrence-free probability curve, and the curve declined further in patients age ≥ 60 years who were *BRAF* V600E mutation positive (Fig 2C).

To further examine the interactions of *BRAF* V600E mutation with clinicopathologic risk factors, we calculated the SI,²⁸ which tests for an additive interaction, representing synergism if the SI is > 1 and antagonism between the two factors if the value is < 1 . We found a significant synergistic interaction between *BRAF* V600E mutation and patient age ≥ 60 years, with an SI of 2.15 (95% CI, 1.11 to 4.19; Table 3).

BRAF V600E mutation was also significantly associated with PTC recurrence in conventionally low-risk patients (Table 4). In patients with stage I PTC, 12.1% (66 of 547) of *BRAF* mutation-positive patients and 7.3% (53 of 726) of *BRAF* mutation-negative patients experienced recurrence. Recurrence rates were significantly higher for *BRAF* mutation-positive versus -negative patients (25.61 ν 15.75 per 1,000 person-years; $P = .008$), with an HR of 1.61 (95% CI, 1.12 to 2.31), which remained significant at 1.56 (95% CI, 1.04 to 2.34) after adjustment for patient age, sex, medical center, tumor size, extrathyroidal invasion, lymph node metastasis, and multifocality. In patients with stage II PTC, 20.7% (19 of 92) of *BRAF* mutation-positive patients and 9.2% (13 of 142) of *BRAF* mutation-negative patients experienced recurrence. Although these numbers were relatively small, *BRAF* mutation was still significantly associated with higher recurrence rates (54.99 ν 22.65 per 1,000 person-years; $P = .01$) and risk (fully adjusted HR, 4.45; 95% CI, 1.70 to 11.67). In patients with micro-PTC, 17.8% (39 of 219) of *BRAF* mutation-positive patients and 5.7% (18 of 315) of *BRAF* mutation-negative patients experienced recurrence. Again, *BRAF* mutation was significantly associated with higher recurrence rates (43.85 ν 13.04 per 1,000 person-years; $P < .001$) and risk (fully adjusted HR, 2.40; 95% CI, 1.00 to 5.75).

Significant effects of *BRAF* V600E mutation on PTC recurrence were also found with various tumor sizes (Appendix Tables A2 and A3, online only). When examined in various patient sex and age categories (Appendix Table A4, online only), significant effects of *BRAF* mutation on PTC recurrence were observed in both male and female patients and patients age ≥ 60 or ≥ 45 years. These effect patterns of *BRAF* mutation were reproduced in CPTC and FVPTC variants. Among most of these categories, the impact of *BRAF* V600E mutation on PTC recurrence was greatest in men age ≥ 60 years (Appendix Table A4, online only).

It is often a challenging task to risk stratify patients with PTC for optimal treatments. In recent years, promise for better prognostication of PTC has come from molecular markers.⁹ The *BRAF* V600E mutation has emerged as one such promising molecular marker that has attracted considerable attention.⁶⁻⁹ However, previous studies, which were relatively small and mostly single institution oriented, yielded inconsistent results, making *BRAF* V600E mutation debatable as a prognostic marker for PTC.²⁹⁻³¹

In this study, we demonstrated a significant association of *BRAF* V600E mutation with recurrence of PTC, which was independent of conventional clinicopathologic risk factors, representing an incremental prognostic value of *BRAF* V600E mutation beyond the power of conventional clinicopathologic risk factors. We also observed a synergistic interaction between *BRAF* V600E mutation and older patient age in affecting PTC recurrence, which was similar to their synergistic effect on PTC-associated patient mortality.¹⁰ It is worth noting that even in conventionally low-risk stage I or II disease and micro-PTC, *BRAF* V600E mutation was strongly associated with recurrence, confirming the findings in a recent smaller study.³² Management of these patients is highly controversial.³³ The prognostic value of *BRAF* V600E mutation may help improve the risk stratification and treatment of these patients.

The prognostic value of *BRAF* V600E mutation in specific individual subtype variants of PTC has been rarely investigated in previous studies.⁶⁻⁹ With the large size of this study, we were able to examine CPTC and FVPTC individually and similarly demonstrated a strong prognostic value of *BRAF* V600E mutation. It was particularly interesting to see, for the first time to our knowledge, a strong association of *BRAF* V600E mutation with recurrence of FVPTC. In fact, *BRAF* V600E mutation showed the most significant association and highest HRs for recurrence of FVPTC compared with CPTC and all PTCs. *BRAF* V600E mutation was previously reported to be most common in infiltrative FVPTC with lymph node metastases and extrathyroidal invasion,³⁴ consistent with the association of *BRAF* V600E mutation with FVPTC recurrence found in this study. FVPTC has been increasingly documented, and some studies have suggested an overall better prognosis than other PTC variants,³⁵ whereas other studies have suggested a prognosis for FVPTC similar to that for CPTC,³⁶ which tends to promote under-treatment in some practices, whereas unnecessary over-treatments may occur in other practices. The prognostic value of *BRAF* V600E mutation in FVPTC may now help better define the vigorous levels of treatment for this cancer.

Table 4. Relationship Between BRAF V600E Mutation and Tumor Recurrence in Low-Risk Clinicopathologic Categories of PTC

Clinicopathologic Category	Tumor Recurrence			Recurrence Rates												
	BRAF V600E Positive		Person-Years of Follow-Up	BRAF V600E Positive			BRAF V600E Negative			Model One*		Model Two†		Model Three‡		
	No.	%		No.	%	Per 1,000 Person-Years	95% CI	Per 1,000 Person-Years	95% CI	P§	HR	95% CI	HR	95% CI	HR	95% CI
Stage I	66 of 547	12.1	53 of 726	7.3	5,941.8	25.61	20.12 to 32.60	15.75	12.03 to 20.62	.008	1.61	1.12 to 2.31	1.58	1.07 to 2.34	1.56	1.04 to 2.34
Stage II	19 of 92	20.6	13 of 142	9.2	919.5	54.99	35.08 to 86.22	22.65	13.15 to 39.00	.01	2.44	1.20 to 4.97	3.22	1.41 to 7.34	4.45	1.70 to 11.67
Tumor ≤ 1.0 cm	39 of 219	17.8	18 of 315	5.7	2,270.2	43.85	32.04 to 60.02	13.04	8.21 to 20.69	< .001	3.33	1.90 to 5.84	2.74	1.50 to 5.02	2.40	1.00 to 5.75

Abbreviations: HR, hazard ratio; PTC, papillary thyroid cancer.
 *Model one was unadjusted.
 †Model two was adjusted for patient age and sex and stratified by medical center.
 ‡Model three was additionally adjusted for tumor size, extrathyroidal invasion, lymph node metastasis, and multifocality (and PTC subtypes for all-types group).
 §P values from Poisson regressions comparing BRAF mutation–positive and –negative groups.

The aggressive role and prognostic value of *BRAF* V600E mutation in PTC can be explained by several molecular mechanisms, including its aberrant regulation of various signaling pathways, such as the MAP kinase pathway, NF κ B pathway, and RASSF1A pathway; upregulation of various pro-oncogenic molecules; and downregulation of various tumor suppressor genes in thyroid cancer.³⁷ *BRAF* V600E mutation also uniquely downregulates thyroid iodide-metabolizing genes, such as sodium-iodide symporter (NIS),³⁷ thus explaining the initial finding of the association of *BRAF* V600E mutation with the loss of radioiodine avidity and hence radioiodine treatment failure in PTC.¹³ The molecular mechanism for the silencing of NIS by *BRAF* V600E mutation was recently demonstrated to involve histone deacetylation at the *NIS* promoter.³⁸

One weakness in this study was the potential patient inhomogeneity, as is often seen in multicenter studies. Some centers treated patients with more-advanced diseases, but the number of such patients was relatively small. Center stratification performed in this study helped minimize the effect of variations among centers. Also, the large multicenter study with worldwide geographic reach makes the findings highly generalizable. The median follow-up time of 36 months was relatively short, but this should have captured most recurrence events, because PTC recurs mostly within the first several years after the initial treatments. Treatment doses of radioiodine varied at different centers. However, within most centers, there was no significant difference in dose between *BRAF* mutation-positive and -negative patients. A higher overall dose of radioiodine was received by *BRAF* mutation-positive patients, presumably because these patients had more aggressive disease, which prompted more-aggressive treatments. This may have caused an underestimation of the effect of *BRAF* V600E mutation on PTC recurrence, because radioiodine treatment has been shown to reduce recurrence of PTC, particularly in patients with high-stage disease.²⁷

In summary, this was a large multicenter study that provided sufficient power to address the prognostic value of *BRAF* V600E mutation for the recurrence of PTC in various clinicopathologic categories. These results, together with the recent demonstration of the strong association of *BRAF* V600E mutation with PTC-associated patient mortality, help establish a prognostic value of *BRAF* V600E mutation in PTC.

Conception and design: Mingzhao Xing

Financial support: Mingzhao Xing

Administrative support: Mingzhao Xing

Provision of study materials or patients: Mingzhao Xing, Ali S.

Alzahrani, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian, Federica Vianello, R. Michael Tuttle, Eyal Robenshtok, James A. Fagin, Efisio Puxeddu, Laura Fugazzola, Agnieszka Czarniecka, Barbara Jarzab, Christine J. O'Neill, Mark S. Sywak, Alfred K. Lam, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Hirotaka Nakayama, Roderick Clifton-Bligh, Giovanni Tallini, Elizabeth H. Holt, Vlasta Sýkorová

Collection and assembly of data: All authors

Data analysis and interpretation: Mingzhao Xing, Kathryn A. Carson

Manuscript writing: All authors

Final approval of manuscript: All authors

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. *CA Cancer J Clin* 61:69-90, 2011
2. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/
3. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* 97:418-428, 1994
4. Tuttle RM, Ball DW, Byrd D, et al: Thyroid carcinoma. *J Natl Compr Canc Netw* 8:1228-1274, 2010
5. Brown RL, de Souza JA, Cohen EE: Thyroid cancer: Burden of illness and management of disease. *J Cancer* 2:193-199, 2011
6. Xing M: *BRAF* mutation in thyroid cancer. *Endocr Relat Cancer* 12:245-262, 2005
7. Xing M: *BRAF* mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. *Endocr Rev* 28:742-762, 2007
8. Kim TH, Park YJ, Lim JA, et al: The association of the *BRAF* (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-analysis. *Cancer* 118:1764-1773, 2012
9. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. *Lancet* 381:1058-1069, 2013
10. Xing M, Alzahrani AS, Carson KA, et al: Association between *BRAF* V600E mutation and mortality in patients with papillary thyroid cancer. *JAMA* 309:1493-1501, 2013
11. Puxeddu E, Moretti S, Elisei R, et al: *BRAF*(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. *J Clin Endocrinol Metab* 89:2414-2420, 2004
12. Fugazzola L, Mannavola D, Cirello V, et al: *BRAF* mutations in an Italian cohort of thyroid cancers. *Clin Endocrinol (Oxf)* 61:239-243, 2004
13. Xing M, Westra WH, Tufano RP, et al: *BRAF* mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol Metab* 90:6373-6379, 2005
14. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al: The oncogene *BRAF* V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻ targeting to the membrane. *Endocr Relat Cancer* 13:257-269, 2006
15. Nakayama H, Yoshida A, Nakamura Y, et al: Clinical significance of *BRAF* (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. *Anticancer Res* 27:3645-3649, 2007
16. Elisei R, Ugolini C, Viola D, et al: *BRAF*(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. *J Clin Endocrinol Metab* 93:3943-3949, 2008
17. Xing M, Clark D, Guan H, et al: *BRAF* mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. *J Clin Oncol* 27:2977-2982, 2009
18. Yip L, Nikiforova MN, Carty SE, et al: Optimizing surgical treatment of papillary thyroid carcinoma associated with *BRAF* mutation. *Surgery* 146:1215-1223, 2009
19. Ricarte-Filho JC, Ryder M, Chitale DA, et al: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for *BRAF*, *PIK3CA*, and *AKT1*. *Cancer Res* 69:4885-4893, 2009
20. Sykorová V, Dvorakova S, Ryska A, et al: *BRAF*V600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. *J Endocrinol Invest* 33:318-324, 2010
21. Czarniecka A, Rusinek D, Stobiecka E, et al: Occurrence of *BRAF* mutations in a Polish cohort of PTC patients: Preliminary results. *Endokrynol Pol* 61:462-466, 2010
22. O'Neill CJ, Bullock M, Chou A, et al: *BRAF*(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. *Surgery* 148:1139-1145, 2010
23. Pelizzo MR, Boschin IM, Barollo S, et al: *BRAF* analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor: A mono-institutional experience. *Clin Chem Lab Med* 49:325-329, 2011

24. Smith RA, Salajegheh A, Weinstein S, et al: Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. *Hum Pathol* 42:500-506, 2011
25. Kim TY, Kim WB, Rhee YS, et al: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. *Clin Endocrinol (Oxf)* 65:364-368, 2006
26. Pacini F, Schlumberger M, Dralle H, et al: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 154:787-803, 2006
27. Cooper DS, Doherty GM, Haugen BR, et al: American Thyroid Association (ATA) Guidelines Taskforce on thyroid nodules and differentiated thyroid cancer: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 19:1167-1214, 2009
28. Hosmer DW, Lemeshow S: Confidence interval estimation of interaction. *Epidemiology* 3:452-456, 1992
29. Sarne DH: A piece of the puzzle: What does BRAF status mean in the management of patients with papillary thyroid carcinoma? *J Clin Endocrinol Metab* 97:3094-3096, 2012
30. Xing M: BRAFV600E mutation and papillary thyroid cancer: Chicken or egg? *J Clin Endocrinol Metab* 97:2295-2298, 2012
31. Puxeddu E, Filetti S: BRAF mutation assessment in papillary thyroid cancer: Are we ready to use it in clinical practice? *Endocrine* 45:341-343, 2014
32. Elisei R, Viola D, Torregrossa L, et al: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study. *J Clin Endocrinol Metab* 97:4390-4398, 2012
33. McLeod DS, Sawka AM, Cooper DS: Controversies in primary treatment of low-risk papillary thyroid cancer. *Lancet* 381:1046-1057, 2013
34. Rivera M, Ricarte-Filho J, Knauf J, et al: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. *Mod Pathol* 23:1191-1200, 2010
35. Lam AK, Lo CY, Lam KS: Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. *Endocr Pathol* 16:323-330, 2005
36. Lin HW, Bhattacharyya N: Clinical behavior of follicular variant of papillary thyroid carcinoma: Presentation and survival. *Laryngoscope* 120:712-716, 2010
37. Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. *Nat Rev Cancer* 13:184-199, 2013
38. Zhang Z, Liu D, Murugan AK, et al: Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. *Endocr Relat Cancer* 21:161-173, 2014

Affiliations

Mingzhao Xing and Ali S. Alzahrani, Johns Hopkins University School of Medicine; Kathryn A. Carson, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; Young Kee Shong and Tae Yong Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; David Viola and Rossella Elisei, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, Pisa; Caterina Mian, University of Padua; Federica Vianello, Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua; Efsio Puxeddu, University of Perugia, Perugia; Laura Fugazzola, University of Milan and Fondazione IRCCS CàGranda, Milan; Giovanni Tallini, University of Bologna School of Medicine, Bellaria Hospital, Bologna, Italy; Bela Bendlová and Vlasta Sýkorová, Institute of Endocrinology, Prague, Czech Republic; Linwah Yip, University of Pittsburgh School of Medicine, Pittsburgh, PA; R. Michael Tuttle, Eyal Robenshtok, and James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Agnieszka Czarniecka and Barbara Jarzab, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Christine J. O'Neill, Mark S. Sywak, and Roderick Clifton-Bligh, University of Sydney, Sydney, New South Wales; Alfred K. Lam, Griffith University School of Medicine, Gold Coast, Queensland, Australia; Garcilaso Riesco-Eizaguirre, Hospital La Paz, Health Research Institute, and Hospital Universitario de Móstoles; Garcilaso Riesco-Eizaguirre and Pilar Santisteban, Biomedical Research Institute Alberto Sols, Spanish Council of Research, and Autonomous University of Madrid, Madrid, Spain; Hirotaka Nakayama, Kanagawa Cancer Center, Yokohama, Japan; and Elizabeth H. Holt, Yale University School of Medicine, New Haven, CT.

Supported by National Institutes of Health (NIH) Grants No. R01CA134225 and RO1CA113507 (M.X.); by Grant No. UL1 RR 025005 from the National Center for Advancing Translational Sciences of NIH and NIH Roadmap for Medical Research (K.A.C.); and by the following funding to individual study centers: National Science Centre Poland Grants No. N N403 194340 (A.C.) and N N401 612440 (B.J.); grants from Griffith Health Institute (Australia; A.K.L.); Grants No. BFU2010-16025, RD06/0020/0060-RD12/0036/0030 FIS, ISCIII, and S2011/BMD-2328 TIRONET (Spain; P.S.); NIH Grant No. RO1-CA50706 and the Byrne Foundation (J.A.F.); Grant No. IG 9338 from the Fondazione Cassa di Risparmio di Perugia and Associazione Italiana per la Ricerca sul Cancro (Italy) and the Beadle Family Foundation (San Antonio, TX; E.P.); Grant No. IGAMH CRNT 13901-4 (Czech Republic; B.B., V.S.); grants from the New South Wales Cancer Institute (C.J.O.) and Cancer Council of New South Wales (Australia; R.C.-B.); Grant No. MIUR 20074zw8la from the Ministero della Istruzione Universitaria e Ricerca Scientifica and the Associazione Italiana per la Ricerca sul Cancro (Italy; G.T.); NIH/National Institute on Aging Grant No. 5R03AG042334-02 (L.Y.); grants from the Ministero della Istruzione Universitaria e Ricerca Scientifica, the Associazione Italiana per la Ricerca sul Cancro, the Istituto Toscano Tumori, and the Ministero della Salute (Italy; D.V., R.E.); and Grant No. CB-2011-03-02 from the Korean Foundation for Cancer Research (South Korea; Y.K.S., T.Y.K.).

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Association Between *BRAF* V600E Mutation and Recurrence of Papillary Thyroid Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Mingzhao Xing

Honoraria: Bayer/Onyx

Consulting or Advisory Role: Bayer/Onyx

Patents, Royalties, Other Intellectual Property: Receiving royalties as coholder of licensed US patent related to *BRAF* V600E mutation in thyroid cancer

Travel, Accommodations, Expenses: Bayer/Onyx

Ali S. Alzahrani

No relationship to disclose

Kathryn A. Carson

No relationship to disclose

Young Kee Shong

Honoraria: Bayer, Genzyme

Consulting or Advisory Role: Bayer, Genzyme

Travel, Accommodations, Expenses: Bayer, Genzyme

Tae Yong Kim

No relationship to disclose

David Viola

Consulting or Advisory Role: SOBI

Speakers' Bureau: Genzyme

Rossella Elisei

Consulting or Advisory Role: Bayer, Genzyme, AstraZeneca, Exelixis

Speakers' Bureau: Bayer, Genzyme, Exelixis

Travel, Accommodations, Expenses: Bayer, Genzyme, AstraZeneca

Bela Bendlová

No relationship to disclose

Linwah Yip

No relationship to disclose

Caterina Mian

No relationship to disclose

Federica Vianello

No relationship to disclose

R. Michael Tuttle

Honoraria: Genzyme, Bayer/Onyx, sanofi-aventis

Consulting or Advisory Role: Genzyme, Bayer/Onyx, sanofi-aventis

Eyal Robenshtok

Consulting or Advisory Role: Genzyme

James A. Fagin

Honoraria: Quest Diagnostics

Consulting or Advisory Role: Novartis

Research Funding: Biomed Valley, AstraZeneca

Expert Testimony: Novo Nordisk

Efisio Puxeddu

Travel, Accommodations, Expenses: IBSA

Laura Fugazzola

Travel, Accommodations, Expenses: Genzyme

Agnieszka Czarniecka

No relationship to disclose

Barbara Jarzab

Honoraria: AstraZeneca, Novartis, Oxigene, Ipsen, SOBI, BiPar/sanofi-aventis, Bayer, Roche, Eisai

Consulting or Advisory Role: SOBI, AstraZeneca

Speakers' Bureau: Eisai

Expert Testimony: AstraZeneca, SOBI

Travel, Accommodations, Expenses: Ipsen, BiPar/sanofi-aventis, Novartis

Christine J. O'Neill

No relationship to disclose

Mark S. Sywak

No relationship to disclose

Alfred K. Lam

No relationship to disclose

Garcilaso Riesco-Eizaguirre

No relationship to disclose

Pilar Santisteban

No relationship to disclose

Hirota Nakayama

No relationship to disclose

Roderick Clifton-Bligh

Consulting or Advisory Role: Amgen, Bayer

Speakers' Bureau: Amgen, Bayer, Novartis, Novo Nordisk

Research Funding: Amgen (Inst), Eisai (Inst)

Giovanni Tallini

No relationship to disclose

Elizabeth H. Holt

No relationship to disclose

Vlasta Sýkorová

No relationship to disclose

Appendix

Table A1. Initial Radioiodine Treatment Doses by *BRAF* V600E Mutation Status in PTC (all types)

Location	No. of Patients	<i>BRAF</i> Mutation Positive		<i>BRAF</i> Mutation Negative		<i>P</i> *
		Median	IQR	Median	IQR	
Medical Center						
Johns Hopkins Hospital	387	76	0 to 100	30	0 to 100	.03
University of Pittsburgh	162	135	106 to 161	105	0 to 134	< .001
Memorial Sloan-Kettering Cancer Center	90	104	30 to 197	75	0 to 150	.05
Yale University	17	158	51 to 243	100	0 to 209	.38
University of Pisa	189	30	30 to 30	30	30 to 30	.60
University of Perugia	117	100	50 to 100	100	50 to 100	.37
University of Milan	110	80	50 to 80	50	0 to 80	.07
University of Padua	135	100	100 to 150	100	100 to 150	.57
University of Bologna	32	100	50 to 100	100	98 to 100	.86
Kanagawa Cancer Center	49	0	0 to 0	0	0 to 0	1.0
Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology	98	100	100 to 100	100	100 to 100	.84
Griffith Medical School	0	—	—	—	—	—
University of Sydney	84	143	108 to 162	162	135 to 270	.26
Hospital La Paz Health Research Institute	66	120	100 to 150	100	100 to 150	.13
Institute of Endocrinology, Prague	221	100	0 to 102	100	0 to 119	.93
University of Ulsan	197	150	150 to 150	150	150 to 150	.008
Country						
United States	656	100	0 to 140	53	0 to 103	< .001
Italy	583	100	30 to 100	50	30 to 100	< .001
Japan	49	0	0 to 0	0	0 to 0	1.0
Poland	98	100	100 to 100	100	100 to 100	.84
Australia	84	143	108 to 162	162	135 to 270	.26
Spain	66	120	100 to 150	100	100 to 150	.13
Czech Republic	221	100	0 to 102	100	0 to 119	.93
South Korea	197	150	150 to 150	150	150 to 150	.008
Overall	1954	100	50 to 150	100	27 to 103	< .001

Abbreviations: IQR, interquartile range; PTC, papillary thyroid cancer.
**P* value from Wilcoxon signed-rank test.

Table A2. Recurrence and HRs for *BRAF* V600E Mutation-Positive Versus -Negative Patients in Various Tumor Size Groups of PTC (all types)

Tumor Size Category (cm)	Recurrence				HR	95% CI	<i>P</i>
	<i>BRAF</i> Mutation Positive		<i>BRAF</i> Mutation Negative				
	No.	%	No.	%			
1.0 to 2.0	68 of 472	14.4	40 of 451	8.9	1.69	1.14 to 2.50	.009
2.0 to 3.0	60 of 292	20.6	37 of 263	14.1	1.66	1.09 to 2.50	.02
3.0 to 4.0	49 of 164	29.9	34 of 171	19.9	1.41	0.90 to 2.19	.13
≥ 4.0	55 of 129	42.6	29 of 146	19.9	1.88	1.20 to 2.95	.006

Abbreviations: HR, hazard ratio; PTC, papillary thyroid cancer.

Table A3. Recurrence per 1,000 Person-Years and Relative Risk in *BRAF* V600E Mutation–Positive Versus –Negative Patients in Various Tumor Size Groups of PTC (all types)

Tumor Size Category (cm)	Recurrence					
	<i>BRAF</i> Mutation Positive		<i>BRAF</i> Mutation Negative		Relative Risk	95% CI
	Per 1,000 Person-Years	95% CI	Per 1,000 Person-Years	95% CI		
1.0 to 2.0	31.71	25.00 to 40.22	18.36	13.47 to 25.03	1.73	1.17 to 2.55
2.0 to 3.0	45.33	35.20 to 58.39	27.36	19.82 to 37.76	1.66	1.10 to 2.50
3.0 to 4.0	64.02	48.39 to 84.71	46.48	33.21 to 65.05	1.38	0.89 to 2.13
≥ 4.0	91.92	70.57 to 119.73	49.28	34.25 to 70.92	1.87	1.19 to 2.92

Abbreviation: PTC, papillary thyroid cancer.

BRAF Mutation and Thyroid Cancer Recurrence

Table A4. Recurrence and HRs for *BRAF* V600E Mutation–Positive Versus –Negative Patients With PTC (all types) in Various Age and Sex Groups

Patient Age (years)	Recurrence				HR	95% CI
	<i>BRAF</i> Mutation Positive		<i>BRAF</i> Mutation Negative			
	No.	%	No.	%		
All PTCs						
All patients						
All ages	213 of 1,017	20.9	125 of 1,082	11.6	1.82	1.46 to 2.28
< 45	75 of 443	16.9	69 of 576	12.0	1.37	0.99 to 1.91
≥ 45	138 of 574	24.0	56 of 506	11.1	2.20	1.61 to 3.00
≥ 60	80 of 251	31.9	31 of 195	15.9	1.84	1.22 to 2.79
Women						
All ages	133 of 767	17.3	86 of 848	10.1	1.72	1.31 to 2.26
< 45	50 of 351	14.2	50 of 468	10.7	1.33	0.90 to 1.98
≥ 45	83 of 416	20.0	36 of 380	9.5	2.08	1.40 to 3.07
≥ 60	50 of 187	26.7	22 of 140	15.7	1.47	0.89 to 2.42
Men						
All ages	80 of 250	32.0	39 of 234	16.7	1.90	1.30 to 2.79
< 45	25 of 92	27.2	19 of 108	17.6	1.30	0.72 to 2.37
≥ 45	55 of 158	34.8	20 of 126	15.9	2.35	1.41 to 3.93
≥ 60	30 of 64	46.9	9 of 55	16.4	3.08	1.46 to 6.51
CPTC						
All patients						
All ages	168 of 813	20.7	79 of 635	12.4	1.75	1.34 to 2.29
< 45	64 of 368	17.4	46 of 345	13.3	1.26	0.86 to 1.85
≥ 45	104 of 445	23.4	33 of 290	11.4	2.33	1.57 to 3.46
≥ 60	56 of 193	29.0	18 of 111	16.2	1.90	1.11 to 3.24
Women						
All ages	104 of 612	17.0	50 of 501	10.0	1.74	1.24 to 2.44
< 45	43 of 296	14.5	30 of 281	10.7	1.35	0.84 to 2.16
≥ 45	61 of 316	19.3	20 of 220	9.1	2.23	1.34 to 3.70
≥ 60	34 of 143	23.8	13 of 81	16.0	1.41	0.74 to 2.70
Men						
All ages	64 of 201	31.8	29 of 134	21.6	1.70	1.09 to 2.65
< 45	21 of 72	29.2	16 of 64	25.0	1.01	0.53 to 1.95
≥ 45	43 of 129	33.3	13 of 70	18.6	2.47	1.32 to 4.63
≥ 60	22 of 50	44.0	5 of 30	16.7	3.90	1.47 to 10.32
FVPTC						
All patients						
All ages	19 of 89	21.4	24 of 342	7.0	2.76	1.51 to 5.06
< 45	6 of 35	17.1	15 of 175	8.6	2.06	0.79 to 5.38
≥ 45	13 of 54	24.1	9 of 167	5.4	3.50	1.49 to 8.23
≥ 60	8 of 16	50.0	4 of 60	6.7	3.43	0.97 to 12.13
Women						
All ages	12 of 70	17.1	21 of 266	7.9	2.17	1.06 to 4.45
< 45	4 of 28	14.3	15 of 143	10.5	1.43	0.47 to 4.36
≥ 45	8 of 42	19.0	6 of 123	4.9	3.50	1.21 to 10.12
≥ 60	5 of 12	41.7	3 of 41	7.3	4.86	0.90 to 26.37
Men						
All ages	7 of 19	36.8	3 of 76	4.0	5.60	1.44 to 21.76
< 45	2 of 7	28.6	0 of 32	0.0	*	
≥ 45	5 of 12	41.7	3 of 44	6.8	2.71	0.64 to 11.45
≥ 60	3 of 4	75.0	1 of 19	5.3	2.18	0.17 to 28.05

Abbreviations: CPTC, conventional papillary thyroid cancer; FVPTC, follicular-variant papillary thyroid cancer; HR, hazard ratio; PTC, papillary thyroid cancer.
 *Could not be estimated.